Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF (VITALITY-HFpEF)
Chronic Heart Failure With Preserved Ejection Fraction
About this trial
This is an interventional treatment trial for Chronic Heart Failure With Preserved Ejection Fraction
Eligibility Criteria
Inclusion Criteria:
- Previous diagnosis of chronic heart failure (HF)
- HF decompensation within 6 months prior to randomization, defined as hospitalization for HF or intravenous (IV) diuretic treatment for HF without hospitalization.
N-terminal pro brain natriuretic peptide (NT-proBNP) ≥300 or brain natriuretic peptide (BNP) ≥100 pg/mL in sinus rhythm, or NT-proBNP
≥600 or BNP ≥200 pg/mL in atrial fibrillation within 30 days prior to randomization
Diagnostic criteria of HFpEF by echocardiography assessed within 12 months prior to randomization (most recent measurement must be used to determine eligibility with no interim event signaling potential deterioration in ejection fraction)
- Left ventricular ejection fraction (LVEF) ≥45% and
Structural changes indicated by at least one of the following parameters:
- Left ventricle (LV) hypertrophy (any of the following: intraventricular septal or posterior wall thickness ≥1.1 cm, and/or LV mass index ≥115 g/m*2 in male and ≥95 g/m*2 in female), or
- Left atrium (LA) enlargement (any of the following: left atrial volume (LAV) index ≥29 ml/m*2, or LAV >58 mL in male and >52 mL in female patients, or LA area >20 cm*2, or LA diameter >40 mm in male and >38 mm in female patients)
- NYHA class II or III at randomization
Exclusion Criteria:
Clinical instability at randomization, defined by
- Any IV treatment within 24h prior to randomization, and/or
- SBP ≥160 mmHg
- SBP <110 mmHg and/or DBP <40 mmHg and/or symptomatic hypotension
- Resting heart rate (HR) <50 or ≥100 beats per minute (bpm)
- Use of IV inotropes at any time between qualifying HF event and randomization
- Previous diagnosis of reduced ejection fraction (EF) (EF <40%)
- Hypertrophic obstructive cardiomyopathy, acute myocarditis, amyloidosis, sarcoidosis, or pericardial disease
- Primary valvular heart disease requiring surgery or intervention, or within 3 months after valvular surgery or intervention, or active endocarditis
- Acute coronary syndrome, including unstable angina, Non ST-elevation myocardial infarction or ST-elevation myocardial infarction, or Coronary artery bypass grafting (CABG) within 60 days prior to randomization, or indication for Percutaneous coronary intervention or CABG at the time of randomization
- Symptomatic carotid stenosis, or transient ischemic attack or stroke within 60 days prior to randomization
- Complex congenital heart disease
Non-cardiac comorbidity (any of the following)
- Estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m*2 calculated by Modification of Diet in Renal Disease formula
- Hepatic insufficiency classified as Child-Pugh B or C
- Morbid obesity with a body mass index >45 kg/m*2
- Malignancy or other non-cardiac condition limiting life expectancy to <1 year, per physician judgment
- Requires continuous home oxygen for severe pulmonary disease or has interstitial lung disease
- Patients with allergies, intolerance or hypersensitivity to investigational drug or any of the excipients
- Concurrent or anticipated use of nitrates or NO donors, phosphodiesterase type V (PDE5) inhibitors, or a Soluble guanylate cyclase (sGC) stimulator
Sites / Locations
- WestSide Medical
- Capitol Interventional Cardiology
- Interventional Cardiology Medical Group
- Penrose-St. Francis Health Services
- Cardiology Associates of Fairfield County, PC
- Cardiology Associates Of South Florida PA
- Cardiovascular and Vein Center of Florida
- Cardiology Associates Research Company
- LifeSpring Research Foundation, LLC
- Southwest Florida Research
- East Coast Institute for Research, LLC
- Cardiology Partners
- Fox Valley Clinical Research Center, LLC
- Advocate Condell Medical Center
- Reid Health
- Research Integrity, LLC
- Heart Clinic of Hammond
- Anne Arundel Health System
- Henry Ford Health System
- Riser Medical Associates
- St. Louis Heart & Vascular, PC
- Glacier View Research Institute
- Bryan Heart
- Wake Forest Baptist Health
- Capital Area Research, LLC
- Carolina Heart Specialists
- Stern Cardiovascular Center
- Clinical Advancement Center, PLLC
- Corporation Lane Research Center
- Clínica DIM
- Instituto de Investigaciones Clínicas San Nicolás
- Centro de Investigaciones Clínicas
- Centro de Medicina Integral e Investigacion Clínica
- Centro de Especialidades Médicas
- Sanatorio Parque S.A.
- Inst. de Cardiología de Corrientes Juana Francisca Cabral
- Centro de Investigaciones Clinicas del Litoral
- Universitätsklinikum St. Pölten
- Krankenhaus St. Josef Braunau
- Ordensklinikum Linz GmbH Elisabethinen
- Medizinische Universität Graz
- Zentrum f. klinische Studien Dr. Hanusch GmbH
- Universitätsklinikum AKH Wien
- Klinik Floridsdorf - Krankenhaus Nord
- Algemeen Stedelijk Ziekenhuis Campus Aalst
- AZ St-Jan Brugge Oostende AV
- UZ Antwerpen
- H. Hartziekenhuis Mol
- AZ Delta
- Multiprofile Hospital for Active Treatment Pazardzhik
- Spec Hosp for Active Treatm in Cardiology Sv Georgi Pernik
- Specialized Hospital for Actrive Treatm of Card - Pleven
- Multiprofile Hospital for Active Treatment Medline Clinic
- MHAT Dr. Bratan Shukerov AD
- Second Medical Center Sofia EOOD
- NMTH Tzar Boris III
- V MHAT
- MHAT Sveta Marina EAD
- University of Alberta
- SMH Cardiology Clinical Trials Inc
- London Health Sciences Centre
- PACE Cardiology Clinic
- Oakville Cardiologists, Inc.
- Cardiovascular CRO Ltd.
- St. Michael's Hospital Health Centre
- Clinique Sante Cardio MC
- Centre De Recherche Du (CRCHUM) - Hotel-Diu
- CardioVasc HR, Inc.
- Hospital General de Medellin
- IPS Centro Cientifico Asistencial S.A.S
- Caja de Compensación Familiar CAFAM
- Mediservis del Tolima IPS S.A.S
- Fundación Cardiovascular de Colombia
- Klinikum der Universität Würzburg
- Zentrum für Klinische Studien Südbrandenburg GmbH
- Herz- und Diabeteszentrum Nordrhein-Westfalen (HDZ NRW)
- Kliniken Maria Hilf GmbH
- St. Vincenz und Elisabeth Hospital, Kathol. Klinikum Mainz
- Klinische Forschung Dresden GmbH
- Cardiologicum Hamburg - Praxen Wandsbek
- KAT General Hospital of Athens
- G. GENNIMATAS General State Hospital of Athens
- University General Hospital of Larissa
- Konstantopoulio General Hospital of Nea Ionia - AGIA OLGA
- "AHEPA" University General Hospital of Thessaloniki
- Hippokration General Hospital of Thessaloniki
- Budai Irgalmasrendi Korhaz
- Magyar Honvedseg Egeszsegugyi Kozpont Honvedkorhaz
- Magyar Honvedseg Egeszsegugyi Kozpont Honvedkorhaz
- Pharma4Trial Kft.
- Kanizsai Dorottya Hospital
- Medifarma-98 Egeszsegugyi, Kereskedelmi es Szolgaltato Kft.
- HaEmek Medical Center
- Hillel Yaffe Medical Center
- Rambam Health Corporation
- Hadassah Hebrew University Hospital Ein Kerem
- Chaim Sheba Medical Center
- Kaplan Medical Center
- The Baruch Padeh Medical Center, Poria
- Health Corporation of the Ziv Medical Center (R.A.)
- Shamir Medical Center (Assaf Harofeh)
- A.O.U. di Bologna Policlinico S.Orsola Malpighi
- A.O.U. di Ferrara
- Asl Roma 6
- ASST Papa Giovanni XXIII
- ASST Spedali Civili di Brescia
- IRCCS Istituto Clinico Humanitas - Humanitas Mirasole S.p.A.
- ASST Grande Ospedale Metropolitano Niguarda
- IRCCS Fondazione Policlinico San Matteo
- A.O.U. di Sassari
- Seikeikai New Tokyo Heart Clinic
- Steel Memorial Yawata Hospital
- Matsuda Cardiovascular clinic
- National Hospital Organization Kobe Medical Center
- Higashi Takarazuka Satoh Hospital
- National Hospital Organization Kanazawa Medical Center
- Iwate Prefectural Central Hospital
- Uji-Tokushukai Medical Center
- Hirakata kohsai Hospital
- Kishiwada Tokushukai Hospital
- Takatsuki Red Cross Hospital
- Osaka Medical College Hospital
- National Hospital Organization Hamada Medical Center
- Minamino Cardiovascular Hospital
- Toho University Omori Medical Center
- Tokyo Women's Medical University Hospital
- National Hospital Organization Iwakuni Clinical Center
- Fukui Prefectural Hospital
- Okayama Rosai Hospital
- Osaka General Medical Center
- Toyama Prefectural Central Hospital
- Hospital Raja Perempuan Zainab II
- Institute Jantung Negara
- Sarawak Heart Centre
- Uniwersytecki Szpital Kliniczny w Bialymstoku
- 10 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ
- CLINICAL MEDICAL RESEARCH Sp. z o. o.
- SPZOZ Centralny Szpital Kliniczny UM w Lodzi
- Szpital Kliniczny Przemienienia Panskiego
- Twoja Przychodnia - Szczecinskie Centrum Medyczne
- Uniwersyteckie Centrum Kliniczne Warszawskiego UM
- IV Wojskowy Szpital Kliniczny z Poliklinika, SPZOZ
- Dolnoslaski Szp. Spec. im T.M. Centrum Medycyny Ratunkowej
- Hospital de Cascais
- CHTS - Hospital Padre Americo
- CHS - Hospital Sao Bernardo
- Hospital Garcia de Orta
- CHLO - Hospital Sao Francisco Xavier
- Hospital da Luz - Lisboa
- CHUP - Hospital Santo Antonio
- Sci-Res. Institute of Complex Cardiovascular Disorders
- Research center of therapy and prophylactic medicine
- Moscow State University n.a. M.V. Lomonosov
- Samara Regional Clinical Cardiology Dispensary n.a. Polyakov
- City hospital #15
- City Pokrovskaya Hospital
- Singapore General Hospital
- National Heart Centre Singapore
- Clinical Trial Systems
- Durban Medical Centre
- Nash Ranjith Research Centre
- TREAD Research cc
- Tiervlei Trial Centre
- Vergelegen Medi-Clinic
- Hospital Clínico Universitario de Santiago de Compostela
- Ciutat Sanitària i Universitària de Bellvitge
- Hospital Sant Joan Despi Moises Broggi
- Hospital Sanitas La Zarzuela
- Hospital Universitario Clinica Puerta de Hierro
- Hospital Álvaro Cunqueiro
- Hospital del Mar
- Hospital Virgen de la Victoria
- Complejo Hospitalario Ntra. Sra. de Valme
- Far Eastern Memorial Hospital
- National Taiwan University Hospital
- Taipei Veterans General Hospital
- Cheng Hsin General Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
Vericiguat up to 10 mg
Vericiguat up to 15 mg
Placebo
Subjects will receive vericiguat (BAY1021189) for 24 weeks, starting at 2.5 mg once daily at randomization and up-titrated to 5 mg at week 2, to 10 mg at week 4, with sham titration at week 6.
Subjects will receive vericiguat (BAY1021189) for 24 weeks, starting at 2.5 mg once daily at randomization and up-titrated to 5 mg at week 2, to 10 mg at week 4, and to 15 mg at week 6.
Subject will receive placebo for 24 weeks, once daily, starting sham up-titration at weeks 2, 4, and 6.